
Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)
Santen announced it will launch its low-dose atropine formulation (Ryjunea) in Germany, following its approval from the European Commission (EC) in June for myopia management. The company characterised its rollout as an exciting step in the battle against …